New Zealand's PHARMAC enters deal with InterPharma for seven cancer drugs and with Bayer over Xarelto, Avelox and Copaxone

New Zealand’s Pharmaceutical Management Agency (PHARMAC) has reached agreement with InterPharma Pty for seven oncology products and has also done a deal with Germany’s Bayer (BAY: DE) for three products.

In summary, the effect of the deal with InterPharma is that:

• the prices and subsidies of the currently listed Ebewe brands of calcium folinate, methotrexate injections, paclitaxel, epirubicin, carboplatin and oxaliplatin will be reduced from December 1, 2010.
• the Ebewe brands of calcium folinate, methotrexate injections and paclitaxel will be awarded Hospital Supply Status from December 1, 2010 to June 30, 2014;
• the Ebewe brands of epirubicin, carboplatin and oxaliplatin will continue to have Hospital Supply Status until June 30, 2012;
• the Ebewe brand of fludarabine phosphate injection will be listed from July 1, 2011 and will be awarded Hospital Supply Status from 1September 1, 2011 to June 30, 2014;
• the currently listed Fludara brand of fludarabine phosphate inj 50mg (originated by Genzyme) will be delisted from Part II of Section H of the Pharmaceutical Schedule from 1 September 2011; and
• the price and subsidy of fludarabine inj 50 mg for ECP (Baxter) will be reduced from